Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Canal

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|March 12, 1992
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cellsM T Dimanche-Boitrel, H Pelletier, P Genne, et al.
Bulletin Du Cancer|March 1, 1994
[Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors]J M Bachaud, N Albin, C Gay, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 6, 2011
Multiscale modeling of composite materials: a roadmap towards virtual testingJ Llorca, C González, J M Molina-Aldareguía, et al.
British Journal of Cancer|January 10, 2008
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationD Balin-Gauthier, J-P Delord, M-J Pillaire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinomaJ P Delord, C Allal, M Canal, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drugA Montazeri, M Boucaud, F Lokiec, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokineticsC Terret, E Erdociain, R Guimbaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical studyM de Forni, M C Malet-Martino, P Jaillais, et al.
Leukemia|February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromesE Solary, L Mannone, D Moreau, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|March 12, 1992
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cellsM T Dimanche-Boitrel, H Pelletier, P Genne, et al.
Bulletin Du Cancer|March 1, 1994
[Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors]J M Bachaud, N Albin, C Gay, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 6, 2011
Multiscale modeling of composite materials: a roadmap towards virtual testingJ Llorca, C González, J M Molina-Aldareguía, et al.
British Journal of Cancer|January 10, 2008
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationD Balin-Gauthier, J-P Delord, M-J Pillaire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinomaJ P Delord, C Allal, M Canal, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
Population pharmacokinetics of carboplatin in childrenE Chatelut, A V Boddy, B Peng, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
Population pharmacokinetics of topotecan: intraindividual variability in total drugA Montazeri, M Boucaud, F Lokiec, et al.
Clinical Pharmacology and Therapeutics|October 3, 2000
Dose and time dependencies of 5-fluorouracil pharmacokineticsC Terret, E Erdociain, R Guimbaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical studyM de Forni, M C Malet-Martino, P Jaillais, et al.
Leukemia|February 24, 2001
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromesE Solary, L Mannone, D Moreau, et al.
Pageof 15